BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Sapacitabine: Phase III amended

Cyclacel amended the ongoing, open-label, U.S. Phase III SEAMLESS trial comparing oral sapacitabine alone and in alternating cycles with Dacogen decitabine vs. Dacogen alone to remove the sapacitabine monotherapy arm. The company said the amendment will "increase the chance of detecting an improvement in survival while staying within our existing budget and forecasted time frame." Cyclacel said it received confirmation from...

Read the full 294 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >